Acute modulation of the cholinergic system in the mouse brain detected by pharmacological resting-state functional MRI

NeuroImage

Volumn 109, Issue , 2015, Pages 151-159

  Shah, Disha ^a   Blockx, Ines ^a   Guns, Pieter Jan ^a   De Deyn, Peter Paul ^b,c,d   Van Dam, Debby ^b   Jonckers, Elisabeth ^a   Delgado y Palacios, Rafael ^a   Verhoye, Marleen ^a   Van der Linden, Annemie ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c Memory Clinic   (Belgium)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MEDETOMIDINE; METHYLSCOPOLAMINE; MILAMELINE; SCOPOLAMINE; SODIUM CHLORIDE; ACETYLCHOLINE; CHOLINERGIC RECEPTOR BLOCKING AGENT;

ANIMAL TISSUE; ARTICLE; BEHAVIOR; BRAIN FUNCTION; BRAIN REGION; CHOLINERGIC SYSTEM; CINGULATE GYRUS; CINGULATE RETROSPLENIAL CORTEX; CINGULATE RHINAL CORTEX; CINGULATE VISUAL CORTEX; CONTEXTUAL MEMORY; CONTROLLED STUDY; DENSITY GRADIENT; DOSE RESPONSE; DRUG ACTIVITY; ECHO PLANAR IMAGING; FUNCTIONAL CONNECTIVITY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HIPPOCAMPUS; MALE; MEMORY; MOUSE; NEUROTRANSMISSION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SCANNER; PASSIVE AVOIDANCE TEST; RESTING STATE NETWORK; SEDATION; THALAMUS; VISUAL RETROSPLENIAL CORTEX; VISUAL RHINAL CORTEX; ANIMAL; BRAIN; C57BL MOUSE; DRUG EFFECTS; IMAGE PROCESSING; METABOLISM; NERVE TRACT; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSIOLOGY; PROCEDURES; REST; SYNAPTIC TRANSMISSION;

ACETYLCHOLINE; ANIMALS; BRAIN; CHOLINERGIC ANTAGONISTS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, INBRED C57BL; NEURAL PATHWAYS; REST; SYNAPTIC TRANSMISSION;

EID: 84921490157     PISSN: 10538119     EISSN: 10959572     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2015.01.009     Document Type: Article

References (68)

1. Aggleton J.P., O'Mara S.M., Vann S.D., Wright N.F., Tsanov M., Erichsen J.T. Hippocampal-anterior thalamic pathways for memory: uncovering a network of direct and indirect actions. Eur. J. Neurosci. 2010, 31:2292-2307.
2. Agrawal R., Tyagi E., Saxena G., Nath C. Cholinergic influence on memory stages: a study on scopolamine amnesic mice. Indian J. Pharmacol. 2009, 41:192-196.
3. Antonova E., Parslow D., Brammer M., Simmons A., Williams S., Dawson G.R., Morris R. Scopolamine disrupts hippocampal activity during allocentric spatial memory in humans: an fMRI study using a virtual reality analogue of the Morris Water Maze. J. Psychopharmacol. 2011, 25:1256-1265.
4. Aquino-Cias J., Aneiros-Riba R., Fernandez-Yero F., Hernandes-Mesa N. Effects of epileptic foci in the visual cortex of the rat on passive avoidance learning. Physiol. Behav. 1972, 8:957-961.
5. Auld D.S., Kornecook T.J., Bastianetto S., Quirion R. Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies. Prog. Neurobiol. 2002, 68:209-245.
6. Bales K.R., Tzavara E.T., Wu S., Wade M.R., Bymaster F.P., Paul S.M., Nomikos G.G. Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-A beta antibody. J. Clin. Invest. 2006, 116:825-832.
7. Biswal B., Yetkin F.Z., Haughton V.M., Hyde J.S. Functional connectivity in the motor cortex of resting human brain using echo-planar MRI. Magn. Reson. Med. 1995, 34:537-541.
8. Blaizot X., Meguro K., Millien I., Baron J.C., Chavoix C. Correlations between visual recognition memory and neocortical and hippocampal glucose metabolism after bilateral rhinal cortex lesions in the baboon: implications for Alzheimer's disease. J. Neurosci. 2002, 22:9166-9170.
9. Brazhnik E.S., Muller R.U., Fox S.E. Muscarinic blockade slows and degrades the location-specific firing of hippocampal pyramidal cells. J. Neurosci. 2003, 23:611-621.
10. Brazhnik E., Borgnis R., Muller R.U., Fox S.E. The effects on place cells of local scopolamine dialysis are mimicked by a mixture of two specific muscarinic antagonists. J. Neurosci. 2004, 24:9313-9323.
11. Buckner R.L., Andrews-Hanna J.R., Schacter D.L. The brain's default network: anatomy, function, and relevance to disease. Ann. N.Y. Acad. Sci. 2008, 1124:1-38.
12. Burwell R.D., Saddoris M.P., Bucci D.J., Wiig K.A. Corticohippocampal contributions to spatial and contextual learning. J. Neurosci. 2004, 24:3826-3836.
13. Buttini M., Yu G.Q., Shockley K., Huang Y., Jones B., Masliah E., Mallory M., Yeo T., Longo F.M., Mucke L. Modulation of Alzheimer-like synaptic and cholinergic deficits in transgenic mice by human apolipoprotein E depends on isoform, aging, and overexpression of amyloid beta peptides but not on plaque formation. J. Neurosci. 2002, 22:10539-10548.
14. Cash D., Roberts T., Ireland M., Williams S., Hunter J., Upton N., Virley D. Visualizing the effects of scopolamine in the rat brain using functional MRI. J. Cereb. Blood Flow Metab. 2005, 25:S366.
15. Ebert U., Kirch W. Scopolamine model of dementia: electroencephalogram findings and cognitive performance. Eur. J. Clin. Invest. 1998, 28:944-949.
16. Fanselow M.S. Contextual fear, gestalt memories, and the hippocampus. Behav. Brain Res. 2000, 110:73-81.
17. Fell J., Fernandez G., Klaver P., Axmacher N., Mormann F., Haupt S., Elger C.E. Rhinal-hippocampal coupling during declarative memory formation: dependence on item characteristics. Neurosci. Lett. 2006, 407:37-41.
18. Fell J., Fernandez G., Lutz M.T., Kockelmann E., Burr W., Schaller C., Elger C.E., Helmstaedter C. Rhinal-hippocampal connectivity determines memory formation during sleep. Brain 2006, 129:108-114.
19. Fernandez G., Tendolkar I. The rhinal cortex: 'gatekeeper' of the declarative memory system. Trends Cogn. Sci. 2006, 10:358-362.
20. Frey K.A., Howland M.M. Quantitative autoradiography of muscarinic cholinergic receptor binding in the rat brain: distinction of receptor subtypes in antagonist competition assays. J. Pharmacol. Exp. Ther. 1992, 263:1391-1400.
21. Golding J.F., Stott J.R. Comparison of the effects of a selective muscarinic receptor antagonist and hyoscine (scopolamine) on motion sickness, skin conductance and heart rate. Br. J. Clin. Pharmacol. 1997, 43:633-637.
22. Harvey J.A., Gormezano I., Cool-Hauser V.A. Effects of scopolamine and methylscopolamine on classical conditioning of the rabbit nictitating membrane response. J. Pharmacol. Exp. Ther. 1983, 225:42-49.
23. Hasselmo M.E. The role of acetylcholine in learning and memory. Curr. Opin. Neurobiol. 2006, 16:710-715.
24. Heidrich A., Rosler M., Riederer P. Pharmacotherapy of Alzheimer dementia: therapy of cognitive symptoms-new results of clinical studies. Fortschr. Neurol. Psychiatr. 1997, 65:108-121.
25. Jonckers E., Van A.J., De V.G., Van der Linden A., Verhoye M. Functional connectivity fMRI of the rodent brain: comparison of functional connectivity networks in rat and mouse. PLoS One 2011, 6:e18876.
26. Kikuchi M., Wada Y., Nanbu Y., Nakajima A., Tachibana H., Takeda T., Hashimoto T. EEG changes following scopolamine administration in healthy subjects. Quantitative analysis during rest and photic stimulation. Neuropsychobiology 1999, 39:219-226.
27. Klinkenberg I., Blokland A. The validity of scopolamine as a pharmacological model for cognitive impairment: a review of animal behavioral studies. Neurosci. Biobehav. Rev. 2010, 34:1307-1350.
28. Kocsis P., Gyertyan I., Eles J., Laszy J., Hegedus N., Gajari D., Deli L., Pozsgay Z., David S., Tihanyi K. Vascular action as the primary mechanism of cognitive effects of cholinergic, CNS-acting drugs, a rat phMRI BOLD study. J. Cereb. Blood Flow Metab. 2014, 34:995-1000.
29. Kuznetsova E., Schliebs R. beta-Amyloid, cholinergic transmission, and cerebrovascular system - a developmental study in a mouse model of Alzheimer's disease. Curr. Pharm. Des. 2013, 19:6749-6765.
30. Law L.M., Smith D.M. The anterior thalamus is critical for overcoming interference in a context-dependent odor discrimination task. Behav. Neurosci. 2012, 126:710-719.
31. Leech R., Sharp D.J. The role of the posterior cingulate cortex in cognition and disease. Brain 2014, 137:12-32.
32. Lein E.S., Hawrylycz M.J., Ao N., Ayres M., Bensinger A., et al. Genome-wide atlas of gene expression in the adult mouse brain. Nature 2007, 445:168-176.
33. Lenartowicz A., McIntosh A.R. The role of anterior cingulate cortex in working memory is shaped by functional connectivity. J. Cogn. Neurosci. 2005, 17:1026-1042.
34. Levey A.I., Kitt C.A., Simonds W.F., Price D.L., Brann M.R. Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. J. Neurosci. 1991, 11:3218-3226.
35. Li W., Antuono P.G., Xie C., Chen G., Jones J.L., Ward B.D., Franczak M.B., Goveas J.S., Li S.J. Changes in regional cerebral blood flow and functional connectivity in the cholinergic pathway associated with cognitive performance in subjects with mild Alzheimer's disease after 12-week donepezil treatment. NeuroImage 2012, 60:1083-1091.
36. Lu H., Zou Q., Gu H., Raichle M.E., Stein E.A., Yang Y. Rat brains also have a default mode network. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:3979-3984.
37. Marchand A., Faugere A., Coutureau E., Wolff M. A role for anterior thalamic nuclei in contextual fear memory. Brain Struct. Funct. 2013, 219:1575-1586.
38. Mesulam M.M. The cholinergic innervation of the human cerebral cortex. Prog. Brain Res. 2004, 145:67-78.
39. Mulholland G.K., Otto C.A., Jewett D.M., Kilbourn M.R., Koeppe R.A., Sherman P.S., Petry N.A., Carey J.E., Atkinson E.R., Archer S. Synthesis, rodent biodistribution, dosimetry, metabolism, and monkey images of carbon-11-labeled (+)-2 alpha-tropanyl benzilate: a central muscarinic receptor imaging agent. J. Nucl. Med. 1992, 33:423-430.
40. Ohno M., Sametsky E.A., Younkin L.H., Oakley H., Younkin S.G., Citron M., Vassar R., Disterhoft J.F. BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease. Neuron 2004, 41:27-33.
41. Ongali B., Nicolakakis N., Lecrux C., Aboulkassim T., Rosa-Neto P., Papadopoulos P., Tong X.K., Hamel E. Transgenic mice overexpressing APP and transforming growth factor-beta1 feature cognitive and vascular hallmarks of Alzheimer's disease. Am. J. Pathol. 2010, 177:3071-3080.
42. Pa J., Berry A.S., Compagnone M., Boccanfuso J., Greenhouse I., Rubens M.T., Johnson J.K., Gazzaley A. Cholinergic enhancement of functional networks in older adults with mild cognitive impairment. Ann. Neurol. 2013, 73:762-773.
43. Penzes P., Buonanno A., Passafaro M., Sala C., Sweet R.A. Developmental vulnerability of synapses and circuits associated with neuropsychiatric disorders. J. Neurochem. 2013, 126:165-182.
44. Pepeu G., Giovannini M.G. Changes in acetylcholine extracellular levels during cognitive processes. Learn. Mem. 2004, 11:21-27.
45. Pradhan S.N., Roth T. Comparative behavioral effects of several anticholinergic agents in rats. Psychopharmacologia 1968, 12:358-366.
46. Riekkinen P., Kuitunen J., Riekkinen M. Effects of scopolamine infusions into the anterior and posterior cingulate on passive avoidance and water maze navigation. Brain Res. 1995, 685:46-54.
47. Risacher S.L., Wang Y., Wishart H.A., Rabin L.A., Flashman L.A., McDonald B.C., West J.D., Santulli R.B., Saykin A.J. Cholinergic enhancement of brain activation in mild cognitive impairment during episodic memory encoding. Front. Psychiatry 2013, 4:105.
48. Rush D.K. Scopolamine amnesia of passive avoidance: a deficit of information acquisition. Behav. Neural Biol. 1988, 50:255-274.
49. Sato A., Sato Y. Cholinergic neural regulation of regional cerebral blood flow. Alzheimer Dis. Assoc. Disord. 1995, 9:28-38.
50. Schneider L.S., Mangialasche F., Andreasen N., Feldman H., Giacobini E., Jones R., Mantua V., Mecocci P., Pani L., Winblad B., Kivipelto M. Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014. J. Intern. Med. 2014, 275:251-283.
51. Schwarz R.D., Callahan M.J., Coughenour L.L., Dickerson M.R., Kinsora J.J., Lipinski W.J., Raby C.A., Spencer C.J., Tecle H. Milameline (CI-979/RU35926): a muscarinic receptor agonist with cognition-activating properties: biochemical and in vivo characterization. J. Pharmacol. Exp. Ther. 1999, 291:812-822.
52. Shah D., Jonckers E., Praet J., Vanhoutte G., Delgado Y.P., Bigot C., D'Souza D.V., Verhoye M., Van der Linden A. Resting state FMRI reveals diminished functional connectivity in a mouse model of amyloidosis. PLoS One 2013, 8:e84241.
53. Sheline Y.I., Raichle M.E. Resting state functional connectivity in preclinical Alzheimer's disease. Biol. Psychiatry 2013, 74:340-347.
54. Snaedal J., Johannesson G.H., Gudmundsson T.E., Gudmundsson S., Pajdak T.H., Johnsen K. The use of EEG in Alzheimer's disease, with and without scopolamine-a pilot study. Clin. Neurophysiol. 2010, 121:836-841.
55. Sperling R., Greve D., Dale A., Killiany R., Holmes J., Rosas H.D., Cocchiarella A., Firth P., Rosen B., Lake S., Lange N., Routledge C., Albert M. Functional MRI detection of pharmacologically induced memory impairment. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:455-460.
56. Spires-Jones T., Knafo S. Spines, plasticity, and cognition in Alzheimer's model mice. Neural Plast. 2012, 2012:319836.
57. Teixeira C.M., Pomedli S.R., Maei H.R., Kee N., Frankland P.W. Involvement of the anterior cingulate cortex in the expression of remote spatial memory. J. Neurosci. 2006, 26:7555-7564.
58. Tice M.A., Hashemi T., Taylor L.A., McQuade R.D. Distribution of muscarinic receptor subtypes in rat brain from postnatal to old age. Brain Res. Dev. Brain Res. 1996, 92:70-76.
59. van Beek A.H., Claassen J.A. The cerebrovascular role of the cholinergic neural system in Alzheimer's disease. Behav. Brain Res. 2011, 221:537-542.
60. van den Heuvel M.P., Hulshoff Pol H.E. Exploring the brain network: a review on resting-state fMRI functional connectivity. Eur. Neuropsychopharmacol. 2010, 20:519-534.
61. van Spronsen M., Hoogenraad C.C. Synapse pathology in psychiatric and neurologic disease. Curr. Neurol. Neurosci. Rep. 2010, 10:207-214.
62. Watanabe T., Yamagata N., Takasaki K., Sano K., Hayakawa K., Katsurabayashi S., Egashira N., Mishima K., Iwasaki K., Fujiwara M. Decreased acetylcholine release is correlated to memory impairment in the Tg2576 transgenic mouse model of Alzheimer's disease. Brain Res. 2009, 1249:222-228.
63. Wess J. Muscarinic acetylcholine receptor knockout mice: novel phenotypes and clinical implications. Annu. Rev. Pharmacol. Toxicol. 2004, 44:423-450.
64. Wess J. Novel muscarinic receptor mutant mouse models. Handb. Exp. Pharmacol. 2012, 95-117.
65. Wink A.M., Bernard F., Salvador R., Bullmore E., Suckling J. Age and cholinergic effects on hemodynamics and functional coherence of human hippocampus. Neurobiol. Aging 2006, 27:1395-1404.
66. Yamada M., Lamping K.G., Duttaroy A., Zhang W., Cui Y., Bymaster F.P., McKinzie D.L., Felder C.C., Deng C.X., Faraci F.M., Wess J. Cholinergic dilation of cerebral blood vessels is abolished in M(5) muscarinic acetylcholine receptor knockout mice. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:14096-14101.
67. Yamada M., Basile A.S., Fedorova I., Zhang W., Duttaroy A., Cui Y., Lamping K.G., Faraci F.M., Deng C.X., Wess J. Novel insights into M5 muscarinic acetylcholine receptor function by the use of gene targeting technology. Life Sci. 2003, 74:345-353.
68. Yan Z., Feng J. Alzheimer's disease: interactions between cholinergic functions and beta-amyloid. Curr. Alzheimer Res. 2004, 1:241-248.